| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Staner, M Kerkhofs, D Detroux, S Leyman, P Linkowski, J Mendlewic. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep. vol 18. issue 6. 1995-11-30. PMID:7481419. |
paroxetine (30 mg), a selective serotonin (5-ht) reuptake inhibitor, was compared in a double-blind trial to amitriptyline (150 mg) in a sample of 40 inpatients aged 18-65 years who fulfilled research diagnostic criteria for major depression. |
1995-11-30 |
2023-08-12 |
Not clear |
| M I Wilde, R Whittingto. Paroxetine. A pharmacoeconomic evaluation of its use in depression. PharmacoEconomics. vol 8. issue 1. 1995-11-29. PMID:10155603. |
there has been intense debate about whether the use of paroxetine or other selective serotonin reuptake inhibitors (ssris) as alternatives to tricyclic antidepressants for first-line treatment of depression can be justified, considering their higher acquisition costs. |
1995-11-29 |
2023-08-12 |
Not clear |
| J D Bentkover, J P Feighne. Cost analysis of paroxetine versus imipramine in major depression. PharmacoEconomics. vol 8. issue 3. 1995-11-29. PMID:10155618. |
a simulation decision analytical model was used to compare the annual direct medical costs of treating patients with major depression using the selective serotonin reuptake inhibitor (ssri) paroxetine or the tricyclic antidepressant (tca) imipramine. |
1995-11-29 |
2023-08-12 |
Not clear |
| b' R Krul\\xc3\\xadk, P Bures, Z Fisar, K Fuksov\\xc3\\xa1, J Sikora, D Beitlov\\xc3\\xa. [Ca(2+)-channel blockers and binding of tricyclic antidepressive agents]. Ceskoslovenska psychiatrie. vol 91. issue 3. 1995-11-20. PMID:7553947.' |
mechanism of ca(2+)-channel blockers action in the treatment of depression may be connected rather with changes in signal transduction through serotonin and catecholamine receptor systems than with direct interaction of drugs with binding sites for tricyclic antidepressants. |
1995-11-20 |
2023-08-12 |
human |
| F Fernández-de-Miguel, P Drapea. Synapse formation and function: insights from identified leech neurons in culture. Journal of neurobiology. vol 27. issue 3. 1995-10-17. PMID:7673895. |
the release of 5-ht is quantal, calcium-dependent, and shows activity-dependent facilitation and depression. |
1995-10-17 |
2023-08-12 |
Not clear |
| M B Keller, D L Hank. Anxiety symptom relief in depression treatment outcomes. The Journal of clinical psychiatry. vol 56 Suppl 6. 1995-09-28. PMID:7649969. |
in studies comparing benzodiazepines, monoamine oxidase inhibitors (maois), serotonin selective reuptake inhibitors (ssris), and tricyclic antidepressants (tcas) in the treatment of concurrent anxiety and depression, all have some measure of success depending on the degree of depression and the type of anxiety disorder. |
1995-09-28 |
2023-08-12 |
Not clear |
| J Mendels, F Reimherr, R N Marcus, D L Roberts, R J Francis, S F Anto. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. The Journal of clinical psychiatry. vol 56 Suppl 6. 1995-09-28. PMID:7649971. |
nefazodone hydrochloride, a 5-ht2 receptor antagonist that selectively inhibits serotonin reuptake, was evaluated in a double-blind, dose-finding study of novel design, involving 240 patients with major depression. |
1995-09-28 |
2023-08-12 |
Not clear |
| K Rickels, D S Robinson, E Schweizer, R N Marcus, D L Robert. Nefazodone: aspects of efficacy. The Journal of clinical psychiatry. vol 56 Suppl 6. 1995-09-28. PMID:7649973. |
nefazodone hydrochloride, a 5-ht2 receptor antagonist and serotonin (5-ht) uptake inhibitor, was evaluated in four phase 3 double-blind, imipramine- and placebo-controlled studies involving outpatients with major depression. |
1995-09-28 |
2023-08-12 |
Not clear |
| H H Berendse. Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacology & therapeutics. vol 66. issue 1. 1995-09-07. PMID:7630928. |
interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? |
1995-09-07 |
2023-08-12 |
Not clear |
| I Hindmarc. The behavioural toxicity of the selective serotonin reuptake inhibitors. International clinical psychopharmacology. vol 9 Suppl 4. 1995-08-31. PMID:7622818. |
the serotonin reuptake inhibitors (ssris) are generally better tolerated than the traditional tricyclic antidepressants (tcas) in the treatment of major depression. |
1995-08-31 |
2023-08-12 |
Not clear |
| D Baldwin, S Rudg. The role of serotonin in depression and anxiety. International clinical psychopharmacology. vol 9 Suppl 4. 1995-08-31. PMID:7622823. |
the role of serotonin in depression and anxiety. |
1995-08-31 |
2023-08-12 |
Not clear |
| D Baldwin, S Rudg. The role of serotonin in depression and anxiety. International clinical psychopharmacology. vol 9 Suppl 4. 1995-08-31. PMID:7622823. |
recent research has identified that various abnormalities in serotonergic function are involved in the pathogenesis of depression and anxiety, and has facilitated the development of new pharmacological agents with great therapeutic potential, for example the selective serotonin reuptake inhibitors (ssris). |
1995-08-31 |
2023-08-12 |
Not clear |
| P Robert, S A Montgomer. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. International clinical psychopharmacology. vol 10 Suppl 1. 1995-08-30. PMID:7622809. |
the aim of the present study was to determine whether, in patients with depression who had responded favourably to the selective serotonin reuptake inhibitor citalopram, there was a therapeutic benefit in continuation treatment. |
1995-08-30 |
2023-08-12 |
Not clear |
| D T Wong, F P Bymaster, E A Englema. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life sciences. vol 57. issue 5. 1995-08-28. PMID:7623609. |
the historical background of the proposed involvement of 5-ht in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed. |
1995-08-28 |
2023-08-12 |
Not clear |
| M Bijak, M Pap. The effect of chronic treatment with imipramine on the responsiveness of hippocampal CA1 neurons to phenylephrine and serotonin in a chronic mild stress model of depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 5. issue 1. 1995-08-24. PMID:7613100. |
the effect of chronic treatment with imipramine on the responsiveness of hippocampal ca1 neurons to phenylephrine and serotonin in a chronic mild stress model of depression. |
1995-08-24 |
2023-08-12 |
rat |
| C Maudhuit, M Hamon, J Adrie. Electrophysiological activity of raphe dorsalis serotoninergic neurones in a possible model of endogenous depression. Neuroreport. vol 6. issue 4. 1995-08-17. PMID:7605927. |
this suggests that neonatal clomipramine treatment results in a long lasting desensitization of somatodendritic 5-ht1a autoreceptors, leading possibly to a dysregulation of 5-ht neurone activity in this proposed model of depression. |
1995-08-17 |
2023-08-12 |
human |
| F Orallo, A Fernández Alzueta, M Campos-Toimil, J M Callej. Study of the in vivo and in vitro cardiovascular effects of (+)-glaucine and N-carbethoxysecoglaucine in rats. British journal of pharmacology. vol 114. issue 7. 1995-08-17. PMID:7606346. |
in isolated intact aorta of rat, (+)-glaucine (0.15-5 microm) competitively inhibited the contractions induced by na (with a pa2 value of 7.14) and non-competitively those induced by 5-ht (in normal krebs solution) and ca2+ (in depolarizing ca(2+)-free high-k+ 50 mm solution), with depression of the maximal response and with pd2 values of 5.56 and 5.26, respectively. |
1995-08-17 |
2023-08-12 |
rat |
| S C Pandey, J M Davis, G N Pande. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. Journal of psychiatry & neuroscience : JPN. vol 20. issue 3. 1995-07-27. PMID:7786883. |
the 5-ht2a receptor subtype is the most widely studied of the 5-ht receptors in psychiatric disorders (for example, suicide, depression and schizophrenia) as well as in relation to the mechanism of action of antidepressant drugs. |
1995-07-27 |
2023-08-12 |
Not clear |
| Y I Sheline, M E Bardgett, J L Jackson, J W Newcomer, J G Csernansk. Platelet serotonin markers and depressive symptomatology. Biological psychiatry. vol 37. issue 7. 1995-07-27. PMID:7786957. |
to examine the specificity of relationships between cognitive and vegetative symptom groupings and platelet serotonin measures, we assessed 35 depressed outpatients using the hamilton rating scale for depression and collected platelets after a minimum 3-week drug-free period. |
1995-07-27 |
2023-08-12 |
Not clear |
| Y I Sheline, M E Bardgett, J L Jackson, J W Newcomer, J G Csernansk. Platelet serotonin markers and depressive symptomatology. Biological psychiatry. vol 37. issue 7. 1995-07-27. PMID:7786957. |
the results showed that depressed patients had lower platelet serotonin (5-ht) uptake site density values than controls and that 5-ht uptake site density values were inversely correlated with the severity of cognitive symptoms of depression. |
1995-07-27 |
2023-08-12 |
Not clear |